These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 10532104)
1. [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors]. Safonova SA; Gershanovich ML; Punanov IuA; Kolygin BA Vopr Onkol; 1999; 45(4):424-8. PubMed ID: 10532104 [TBL] [Abstract][Full Text] [Related]
2. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429 [TBL] [Abstract][Full Text] [Related]
4. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial. Lajolo PP; de Camargo B; del Giglio A Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119 [TBL] [Abstract][Full Text] [Related]
5. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147 [TBL] [Abstract][Full Text] [Related]
6. [The 5HT3-receptor antagonist Zofran (ondansetron) as an agent for preventing nausea and vomiting during the cytostatic treatment of cancer patients]. Perevodchikova NI; Volkova MA; Gorbunova VA; Manziuk LV; Marenich AF; Smirnova NB Ter Arkh; 1996; 68(2):30-4. PubMed ID: 8771653 [TBL] [Abstract][Full Text] [Related]
7. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486 [TBL] [Abstract][Full Text] [Related]
8. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin]. Harousseau JL Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859 [TBL] [Abstract][Full Text] [Related]
9. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735 [TBL] [Abstract][Full Text] [Related]
10. Granisetron and ondansetron for chemotherapy-related nausea and vomiting. Zeidman A; Ben Dayan D; Ben Zion T; Kaufman O; Cohen AM; Mittelman M Haematologia (Budap); 1998; 29(1):25-31. PubMed ID: 9704254 [TBL] [Abstract][Full Text] [Related]
11. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting. Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A J BUON; 2007; 12(2):245-52. PubMed ID: 17600880 [TBL] [Abstract][Full Text] [Related]
12. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736 [TBL] [Abstract][Full Text] [Related]
13. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706 [TBL] [Abstract][Full Text] [Related]
14. Acute and delayed nausea and emesis control in pediatric oncology patients. Holdsworth MT; Raisch DW; Frost J Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy. Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666 [TBL] [Abstract][Full Text] [Related]
17. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978 [TBL] [Abstract][Full Text] [Related]
18. [Novel pharmacologic form of ondansetron (Zofran)--lingual tablets in the prevention of cytostatic chemotherapy-induced loss of appetite, nausea and vomiting]. Gershanovich ML; Beresneva IA; Makhnova EV Vopr Onkol; 2003; 49(4):505-9. PubMed ID: 14569947 [TBL] [Abstract][Full Text] [Related]